Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Up 7.37%
As of Wednesday, October 28, Ocular Therapeutix, Inc.’s OCUL share price has surged by 7.37%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Commentary & Analysis
Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Up 5.88%
As of Tuesday, October 20, Ocular Therapeutix, Inc.’s OCUL share price has surged by 5.88%, which has investors questioning if this is right time to sell.Michael Rose
Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Down 8.95%
As of Monday, October 19, Ocular Therapeutix, Inc.’s OCUL share price has dipped by 8.95%, which has investors questioning if this is right time to buy.Michael Rose
Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Down 10.41%
As of Monday, October 19, Ocular Therapeutix, Inc.’s OCUL share price has dipped by 10.41%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Down 6.10%
As of Friday, October 16, Ocular Therapeutix, Inc.’s OCUL share price has dipped by 6.10%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,412.1 | $409.9 | 50% |
|
| Shares Out (Mil) | 225.0 | 44.5 | 78% |
|
| Institutional Ownership | 98.5% | 81.1% | 79% |
|
| Float (Mil) | 184.7 | 45.7 | 72% |
|
| Beta | 0.97 | 0.72 | 58% |
|
| Avg Daily Volume (000s) | 2,383 | 284 | 83% |
|
| Price Change (52-week) |
(41.0%) | 52.7% | 24% |
|
| Growth | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 24.5% | 5.7% | 86% |
|
| Net Income (5yr) | (11.3%) | (2.0%) | 28% |
|
| EPS (5yr) | 11.1% | 14.9% | 49 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (8.4%) | (15.1%) | 59% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 5 | 6 | |
| Current EPS | ($0.355) | ($1.444) | ($1.480) | |
| Month Ago EPS | ($0.352) | ($1.430) | ($1.454) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.350) | ($1.393) | ($1.466) | |
| Year/Year Chg | 1.4% | 1.7% | (21.4%) | |
| Financials | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $52 | $326 | 20% |
|
| Net Income (TTM) (Mil) | ($301) | ($11) | 5% |
|
| EPS (TTM) | ($1.409) | ($0.600) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($238) | ($6) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $208 | $2 | 84% |
|
| Long-Term Debt (Q1) (Mil) | $76 | $6 | 42% |
|
| Enterprise Value (Q1) (Mil) | $1,675 | $466 | 47% |
|
| Valuation | OCUL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.71 | 1.96 | 66% |
|
| P/E | na | 20.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (342.3%) | 67.7% | 1% |
|
| Net Margin | (579.1%) | 3.4% | 1% |
|
| ROA | (53.7%) | (21.5%) | 11% |
|
| ROE | (73.0%) | (21.0%) | 12% |
|
| Liabilities to Assets | 22.5% | 31.8% | 15% |
|
| F-Score | 2 | 3 | 7% |
|
Ocular Therapeutix, Inc. did not pass any screens on 11/5/2026.
